SG/PUT/VERTEX PHARMACEUTICALS/300/0.1/20.09.24 | Delayed Deutsche Boerse AG 05:06:48 2024-06-13 EDT | ||
| 0.053 EUR | -24.29% |
|
| Current month | -30.00% | ||
| 1 month | -41.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-13 | 0.053 | -24.29% |
| 24-06-12 | 0.07 | +42.86% |
| 24-06-11 | 0.049 | +16.67% |
| 24-06-10 | 0.042 | -23.64% |
| 24-06-07 | 0.055 | -31.25% |
Delayed Quote Deutsche Boerse AG
Last update June 13, 2024 at 05:06 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SV6Q1H |
| ISIN | DE000SV6Q1H1 |
| Date issued | 2023-05-24 |
| Strike | 300 $ |
| Maturity | 2024-09-20 (100 Days) |
| Parity | 10 : 1 |
| Emission price | 3.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.51 € |
|---|---|
| Lowest since issue | 0.018 € |
| Spread | 0.067 € |
| Spread % | 55.83% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475.8
USD
Average target price
463.4
USD
Spread / Average Target
-2.60%
- Stock Market
- Warrants
- Warrant
